Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Neoplasms 14Colorectal Neoplasms 14Melanoma 12Carcinoma, Renal Cell 11Neoplasm Metastasis 9Solid Tumors 8Carcinoma, Hepatocellular 8Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Lymphoma 5Kidney Neoplasms 4Endometrial Neoplasms 4Solid Tumor 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Advanced Solid Tumors 3Urologic Neoplasms 2Treatment-Refractory Solid Tumors 2Solid Cancers 2Recurrence 2

Interventions

radium Ra 223 dichloride 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Castrate-Resistant Prostate Cancer × atezolizumab × Clear all
NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Hoffmann-La Roche

Phase 1 Completed
45 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡